摘要
目的:比较用伊立替康联合奈达铂与伊立替康联合顺铂治疗小细胞肺癌的效果。方法:选择2017年7月至2019年7月期间重庆大学附属肿瘤医院收治的64例小细胞肺癌患者作为研究对象。将这些患者随机平均分为对照组和观察组。为对照组患者使用伊立替康联合奈达铂实施治疗。为观察组患者使用伊立替康联合顺铂实施治疗。然后,比较两组患者的疗效、无进展生存期、3个月生存率、6个月生存率、1年生存率及不良反应(包括腹泻、骨髓抑制、血小板减少等)的发生率。结果:治疗后,两组患者治疗的总有效率、无进展生存期、3个月生存率、6个月生存率、1年生存率及不良反应的总发生率相比,P>0.05。结论:用伊立替康联合奈达铂或顺铂治疗小细胞肺癌的效果均很好。用伊立替康联合奈达铂或顺铂治疗小细胞肺癌后,患者的疗效、生存的情况及不良反应的发生率均无显著差异。
Objective:To compare the efficacy of irinotecan combined with nedaplatin and irinotecan combined with cisplatin in the treatment of small cell lung cancer.Methods:64 patients with small cell lung cancer admitted to the Affiliated Cancer Hospital of Chongqing University from July 2017 to July 2019 were selected as study subjects.These patients were randomly divided into an average control group and an observation group.Patients in the control group were treated with irinotecan combined with nedaplatin.Patients in the observation group were treated with irinotecan combined with cisplatin.Then,the efficacy,progression-free survival,3-month,6-month,1-year survival,and the incidence of adverse events(including diarrhea,myelosuppression,thrombocytopenia,etc.)were compared between the two groups.Results:after treatment,the total response rate,progression-free survival rate,3-month survival rate,6-month survival rate,1-year survival rate,and the total incidence of adverse reactions were compared between the two groups(P>0.05).Conclusion:Irinoticam combined with nedaplatin or cisplatin are effective in the treatment of small cell lung cancer.Irinoticam combined with nedaplatin or cisplatin in the treatment of small cell lung cancer showed no significant difference in efficacy,survival and incidence of adverse reactions.
作者
陈静
CHEN Jing(Affiliated Cancer Hospital of Chongqing University,Chongqing 400000)
关键词
小细胞肺癌
伊立替康
顺铂
奈达铂
生存率
不良反应
small cell lung cancer
Irinotecan
Cisplatin
Nida’s platinum
Survival rate
Adverse reactions
